Advertisements


Inovio announces interim clinical data of INO-4800 coronavirus vaccine candidate

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 30th, 2020

Inovio"s Manufacturing, Scalability Concerns Of Coronavirus Vaccine Keeps This Analyst On The Sidelines

Inovio Pharmaceuticals Inc (NASDAQ: INO) reported Tuesday interim Phase 1 readout for INO-4800, its DNA vaccine candidate against the novel coronaviru Lat.....»»

Category: blogSource: benzingaJun 30th, 2020

Benchmark analyst expects FDA to allow Inovio"s coronavirus vaccine to move to Phase 2/3 clinical

A Benchmark Research analyst expects that the Food and Drug Administration will allow Inovio Pharmaceuticals Inc.'s COVID-19 vaccine candidate to move to a Phase 2/3 study. Benchmark's Aydin Huseynov noted that while the Phase 1 efficacy data.....»»

Category: topSource: marketwatchJun 30th, 2020

Lonza Group shares climb on positive Moderna vaccine trial

Shares of Lonza Group climbed 2.9% in Swiss trade after Moderna reported positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus. The companies intend to ma.....»»

Category: topSource: marketwatchMay 18th, 2020

After months of speculation, investors get excited about Pfizer, BioNTech’s coronavirus vaccine candidate

The path to a COVID-19 vaccine has started to come into view this week, following the stock-moving disclosures of preliminary clinical data for two candidates and a rigorous new regulatory road map from the Food and Drug Administration......»»

Category: topSource: marketwatchJul 1st, 2020

Inovio Plunges On Interim Phase 1 Coronavirus Data; DNA Vaccine Shows 94% Response Rate

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were moving to the downside Tuesday after the vaccine maker released interim Phase 1 data for the study that is evaluating its DNA vaccine read more.....»»

Category: blogSource: benzingaJun 30th, 2020

Sinovac Makes Headway In Coronavirus Vaccine Race With Positive Preliminary Phase 1/2 Results

Chinese biopharma Sinovac Biotech, which is one of 10 companies doing human testing of a vaccine candidate for SARS-CoV-2, the virus that causes COVID-19, announced positive preliminary data Monday from Phase 1/2 clinical trials read more.....»»

Category: blogSource: benzingaJun 15th, 2020

Moderna announces interim Phase 1 data for mRNA vaccine against coronavirus

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 18th, 2020

Moderna Rallies On Positive Phase 1 Coronavirus Vaccine Data, Aims For Phase 3 Trial In July

Moderna Inc (NASDAQ: MRNA) shares were skyrocketing Monday after the company announced a positive interim Phase 1 readout for its coronavirus vaccine candidate mRN read more.....»»

Category: blogSource: benzingaMay 18th, 2020

Moderna announces positive interim clinical data in Phase 1 trial of COVID-19 vaccine

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchMay 18th, 2020

COVID-19 Vaccine Updates: J&J Identifies Lead Candidate, IMV Eyes Clinical Testing In Summer, Altimmune Partners With University Of Alabama

Two coronavirus vaccine candidates are in the clinics and 42 more are in preclinical studies, according to updated data provided by the World Health Organization on March 20. read more.....»»

Category: blogSource: benzingaMar 30th, 2020

Inovio"s stock falls as it discloses early-stage data for its COVID-19 vaccine candidate

Shares of Inovio Pharmaceuticals Inc. tumbled 10.8% in premarket trading on.....»»

Category: topSource: marketwatchJun 30th, 2020

Inovio Faces Shareholder Lawsuit Over 3-Hour Coronavirus Vaccine Claim, Company Says DNA Medicine Misunderstood

Inovio Pharmaceuticals Inc (NASDAQ: INO) shareholders are suing the company in U.S. District Court alleging the vaccine maker misled investors by saying it came up with a coronavirus vaccine candidate in about three hours. read more.....»»

Category: blogSource: benzingaJun 16th, 2020

BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

JERUSALEM, June 12, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, to.....»»

Category: earningsSource: benzingaJun 12th, 2020

What You Need To Know About Moderna"s Insider Selling

Moderna Inc (NASDAQ: MRNA) has been one of the hottest stocks of 2020 due to its coronavirus (COVID-19) vaccine candidate currently undergoing clinical trials. read more.....»»

Category: blogSource: benzingaMay 27th, 2020

A Chinese biotech just published the first human data for its coronavirus vaccine candidate, supporting further trials

Associated Press An experimental coronavirus vaccine developed by a Chinese biotech became the first candidate to publish human data in a medical journal. Researchers that .....»»

Category: topSource: businessinsiderMay 22nd, 2020

Market Snapshot: Dow soars more than 700 points, after favorable, early results for coronavirus vaccine candidate

U.S. stocks climbed at the start of Monday after drugmaker Moderna announces positive, early results from its first human trial of its experimental Covid-19 vaccine......»»

Category: topSource: marketwatchMay 18th, 2020

Moderna"s stock soars on positive early-stage data for its coronavirus vaccine candidate

Shares of Mo.....»»

Category: topSource: marketwatchMay 18th, 2020

Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report

Despite Inovio Pharmaceuticals Inc's (NASDAQ: INO) first-quarter miss Monday, the sell-side remains largely upbeat on company, which is developing a coronavirus vaccine candidate.  The Inovio Analysts Stifel analyst S.....»»

Category: earningsSource: benzingaMay 12th, 2020

Inovio Analysts Project About 24% Upside Potential Amid Optimism On Coronavirus DNA Vaccine

Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the completion of enrollment in the Phase 1 trial of its COVID-19 DNA vaccine INO-4800 .....»»

Category: blogSource: benzingaApr 29th, 2020

Inovio and GeneOne announces interim data from Phase 1/2a trial of INO-4700

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 28th, 2020